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Background
MicroRNA regulate the activity of protein-coding genes including those involved in hematopoi-
etic cancers. The aim of the current study was to explore which microRNA are unique for
seven different subtypes of pediatric acute lymphoblastic leukemia.
Design and Methods
Expression levels of 397 microRNA (including novel microRNA) were measured by quantita-
tive real-time polymerase chain reaction in 81 cases of pediatric leukemia and 17 normal
hematopoietic control cases. 
Results
All major subtypes of acute lymphoblastic leukemia, i.e. T-cell, MLL-rearranged, TEL-AML1-
positive, E2A-PBX1-positive and hyperdiploid acute lymphoblastic leukemia, with the excep-
tion of BCR-ABL-positive and ‘B-other’ acute lymphoblastic leukemias (defined as precursor B-
cell acute lymphoblastic leukemia not carrying the foregoing cytogenetic aberrations), were
found to have unique microRNA-signatures that differed from each other and from those of
healthy hematopoietic cells. Strikingly, the microRNA signature of TEL-AML1-positive and
hyperdiploid cases partly overlapped, which may suggest a common underlying biology.
Moreover, aberrant down-regulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblas-
tic leukemia was linked to up-regulation of oncoprotein c-Myc (PFDR<0.0001). Resistance to vin-
cristine and daunorubicin was characterized by an approximately 20-fold up-regulation of miR-
125b, miR-99a and miR-100 (PFDR≤0.002). No discriminative microRNA were found for pred-
nisolone response and only one microRNA was linked to resistance to L-asparaginase. A com-
bined expression profile based on 14 microRNA that were individually associated with prog-
nosis, was highly predictive of clinical outcome in pediatric acute lymphoblastic leukemia (5-
year disease-free survival of 89.4%±7% versus 60.8±12%, P=0.001).  
Conclusions
Genetic subtypes and drug-resistant leukemic cells display characteristic microRNA signatures
in pediatric acute lymphoblastic leukemia. Functional studies of discriminative and prognosti-
cally important microRNA may provide new insights into the biology of pediatric acute lym-
phoblastic leukemia.
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Introduction
The discovery of regulatory microRNA (miRNA) genes
and their biological roles are part of extensive ongoing
studies. These approximately 21-nucleotide miRNA inhibit
the activity of the majority of all human genes at the post-
transcriptional level.1 Usually, miRNA establish such inhi-
bition through imperfect base-pairing with the 3’ untrans-
lated region of a protein-coding messengerRNA (mRNA)
resulting in inhibition of the translation itself or in degrada-
tion/destabilization of its target mRNA.2,3 By doing so, they
are involved in various biological processes such as
hematopoiesis, differentiation and apoptosis. For example,
miR-181a is preferentially expressed in precursor B cells
and stimulation of miR-181a in hematopoietic progenitors
resulted in differentiation towards a more mature B-cell
phenotype.4 Family member miR-181b is mainly present in
mature B cells such as germinal center B cells and its
expression decreases upon further differentiation into plas-
ma or memory B cells.5 miR-15a and miR-16 promote
apoptosis by targeting anti-apoptotic Bcl-2 in hematopoiet-
ic cells.6 Such miRNA-affected processes have been found
to be dysregulated in various different hematopoietic
malignancies. Deletion or down-regulation of miR-15a and
miR-16 in patients with chronic lymphocytic leukemia
protects the leukemic cells from apoptosis6 and amplifica-
tion of the miR-17-92 cluster accelerates the development
of c-myc-induced lymphomas in mice.6,7
Children with some subtypes of acute lymphoblastic
leukemia (ALL), such as hyperdiploid (>50 chromosomes)
and TEL-AML1-translocated ALL, have a favorable 5-year
disease-free survival of more than 85% after combination
chemotherapy.8 However, children with other subtypes,
such as BCR-ABL-positive and mixed lineage leukemia
(MLL)-rearranged ALL, have an unfavorable outcome with
a 5-year disease-free survival of only about 50%.9,10 Besides
the genetic subtype, cellular drug resistance influences the
outcome of children with ALL.11-14 Understanding miRNA
expression levels in different genetic subgroups of ALL
may provide new insights into the biology of the underly-
ing genetic abnormalities and/or drug resistance. To this
aim we used stem-loop-based reverse-transcriptase (RT)
quantitative real-time polymerase chain reaction (PCR)
(stem-loop RT-qPCR) to measure the expression of 397
miRNA in 81 pediatric ALL cases reflecting different genet-
ic subtypes i.e. T-ALL, precursor B-ALL with hyper-
diploidy, MLL-rearrangement, TEL-AML1, BCR-ABL, E2A-
PBX1 and precursor B-ALL not carrying these cytogenetic
aberrations (‘B-other’) and also in 17 control, non-leukemic
hematopoietic cell samples. Furthermore, we studied
whether the miRNA expression profiles were related to
resistance to four important drugs used in ALL treatment,
i.e. prednisolone, vincristine, L-asparaginase, and daunoru-
bicin, and whether miRNA were associated with the clini-
cal outcome of patients.
Design and Methods
Patients’ samples
Mononuclear cells were isolated from peripheral blood or bone
marrow samples collected from 81 children with newly diagnosed
ALL and 17 control cases using sucrose density centrifugation.11,15
The percentage of leukemic cells was determined from May-
Grünwald-Giemsa (Merck, Darmstadt, Germany) stained
cytospins. If the percentage of leukemic cells was below 90%,
samples were enriched by eliminating non-malignant cells with
immunomagnetic beads (see the Online Supplementary Text for
more details).11,15 CD34+-cells (> 90% purity) were sorted from
granulocyte colony-stimulating factor-stimulated blood cell sam-
ples from children with a brain tumor or Wilms’ tumor (Online
Supplementary Text).16 Thymocytes were isolated from thymic
lobes that were resected from children during surgery for congen-
ital heart disease (Online Supplementary Text).17 Samples were col-
lected with informed consent from parents or guardians with local
institutional review board approval. The immunophenotype and
genetic subtype were determined by routine diagnostic proce-
dures including flow cytometry for lineage-detection (T-ALL or
precursor B-ALL), fluorescence in situ hybridization (FISH) and RT-
PCR for genetic subtype and conventional karyotyping to deter-
mine the ploidy status of ALL cases. A total of 10 MLL, 14 TEL-
AML1, 10 BCR-ABL, 9 E2A-PBX1, 13 hyperdiploid and 14 ‘B-
other’ B-ALL (negative for the five previously listed genetic abnor-
malities) and 11 T-ALL cases were included. These cases were ret-
rospectively selected based on availability of material and the
patients were treated with different protocols. Expression levels in
normal hematopoietic cells were determined in seven normal
bone marrow samples, four CD34+-sorted fractions and six thy-
mocyte fractions.
Drug resistance
To determine cellular drug resistance, the concentrations of
prednisolone, vincristine, L-asparaginase or daunorubicin that
were lethal to 50% (LC50) of the ALL cells were measured by MTT
drug resistance assay as described previously (Online Supplementary
Text).11,18 Median LC50 values were used to define cases as sensitive
(≤median LC50) or resistant (>median LC50) to each drug.
Expression analysis 
Total RNA was extracted with TRIzol reagent (Invitrogen,
Leek, the Netherlands) according to the manufacturer’s protocol.
The 2100 bioanalyzer (Agilent, Amstelveen, the Netherlands) was
used to determine the quality of total RNA. All RNA samples had
an RNA Integrity Number of 7.5 or more.
Expression levels of 397 miRNA were analyzed by stem-loop
RT-qPCR microRNA arrays (Applied Biosystems, Foster City, CA,
USA).19 Three hundred and sixty-five miRNA were assayed using
TaqMan MicroRNA arrays with 100 ng of RNA as the input for
each RT reaction according to the manufacturer’s protocol. An
additional 32 miRNA (Online Supplementary Table S1) were meas-
ured using miRNA assays that were custom designed by Applied
Biosystems since these miRNA were not covered by the TaqMan
MicroRNA array platform and/or were recently identified by our
cloning study.16 RT reactions for custom miRNA assays were per-
formed in duplicate, in a total volume of 15 mL containing 0.5 mM
dNTP, 10 U/mL RT, 1x RT buffer, 0.25 U/mL RNase inhibitor and
0.25x multiplex RT primer pool covering the 32 miRNA (Applied
Biosystems). RT reactions were incubated as previously
described.19 Next, cDNA samples were diluted 10-fold in water.
Duplicate PCR reactions of 15 µL were performed in a 96-well
plate for each of the 32 miRNA. PCR reaction mixtures contained
1 µL of diluted cDNA sample in 1x Universal TaqMan Master Mix
and 1x specific primer/probe mix. PCR reactions were performed
on an ABI 7900HT Sequence Detection System. Duplicate meas-
urements of two independent experiments were strongly correlat-
ed (Rs=0.9, P<0.0001, Online Supplementary Figure S1A). Moreover,
multiple measurements for snoR-13 and snoR-14 were analyzed
within one TaqMan Microarray-plate and were also strongly cor-
related (Rs≥0.96, P<0.0001, Online Supplementary Figure S1B,C).
The means of the Ct values for snoR-13 and -14 (TaqMan
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MicroRNA array) and snoR-1 (custom reactions) were used as  ref-
erences to normalize the expression of miRNA. These snoRNA
were chosen since expression levels did not differ significantly
between genetic subtypes of ALL or between ALL samples and
hematopoietic control cells (Online Supplementary Figure S2) and
expression levels of these three snoRNA were strongly correlated
with each other (Online Supplementary Figure S3). The expression
was calculated as a percentage of snoRNA as 2-ΔCt x100% where
the ΔCt is equal to the Ct-value for each miRNA minus the Ct-
value of the control snoRNA. Processed miRNA expression values
have been deposited in the NCBI Gene Expression Omnibus and
are accessible through GEO series accession number GSE23024 at
http://www.ncbi.nlm.nih.gov/geo.
Affymetrix U133 plus 2.0 GeneChips (Santa Clara, CA, USA)
were used to study mRNA expression levels of potential miRNA-
target genes in ALL patients as described earlier (Online
Supplementary Text).20 Reverse phase protein detection was used to
determine the protein level of Ras and c-Myc as previously
described21-23 (Online Supplementary Text).
Statistical analysis
The Wilcoxon rank-sum test was used to compare miRNA
expression levels between two groups. Differences were consid-
ered statistically significant if Benjamini-Hochberg’s false discov-
ery rate -corrected P values (PFDR) were less than 0.05.24 R version
2.825 and the R package multtest (which corrects the P values for
multiple testing)26 were used to perform these analyses. 
Hierarchical clustering of patients by miRNA expression levels
was done using GeneMaths 2.0 software (Applied Maths, Sint-
Martens-Latem, Belgium) after Pearson’s correlation as the dis-
tance measure. Since TaqMan MicroRNA Arrays and custom-
made assays make use of different control snoRNA to correct for
small RNA input, we calculated Z-scores for each miRNA. Z-
scores were used for hierarchical clustering analyses. 
Cox proportional hazard analysis was used to identify miRNA
that correlated with the disease-free survival of children with
newly diagnosed ALL. Both univariate and multivariate (corrected
for ALL subtype) analyses were performed using relapse as the
event and miRNA expression as a continuous variable.
microRNA expression profiles in pediatric ALL
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Figure 1. Clustering of ALL
subtypes and normal
hematopoietic control cells
by expression levels of 325
miRNA. Hierarchical cluster-
ing of ALL patients, normal
bone marrow samples,
CD34+ selected cells and
thymocytes by expression
levels of 325 (unselected)
miRNA. Heatmap shows
which miRNA are overex-
pressed (in red) and which
are underexpressed (in
green) relative to snoRNA
input control. Expression lev-
els are plotted as standard-
ized Z-scores per miRNA. 
Multivariate analysis indicated that the expression levels of 14
miRNA were of significant prognostic value (P<0.05; see results
section). To visualize the prognostic value of the expression signa-
ture of these 14 miRNA, we first divided the cases in two groups
based on the median expression level per miRNA (see Online
Supplementary Table S2 for the median value of each of the 14
miRNA). Patients with high expression (above the median) of a
prognostically favorable miRNA (e.g. miR-10a) were assigned a
score of 1 whereas patients with low expression (below the medi-
an) were given a score of 2. In the case of a prognostically unfavor-
able miRNA (e.g. miR-33), patients were assigned a score 2 in the
case of an expression level above the median and a score of 1 if
this level was below the median. Next, the sum of the individual
scores for the 14 prognostically informative miRNA was calculat-
ed: this resulted in a minimum cumulative score of 14 and a max-
imum cumulative score of 28. The median of the cumulative
scores for 78 patients was used to assign patients to a favorable
(cumulative score ≤21, n=41) or unfavorable (cumulative score
>21, n=37) group in order to study the prognostic value of a com-
bined miRNA expression signature. 
Results
Distinct microRNA profiles in genetic subtypes acute
lymphoblastic leukemia
The expression of 397 miRNA was measured in 81 pedi-
atric ALL cases representing seven different subtypes of
ALL and 17 control cases. This analysis included miR-1972,
miR-1974, miR-1975, miR-1976, miR-1977, miR-1978 and
miR-1979, which we recently discovered as reported else-
where.16 Online Supplementary Table S2 shows the relative
expression of all miRNA in the different subtypes of ALL
and normal hematopoietic cells. Seventy-two (18%)
miRNA were not expressed in at least 97 out of 98 cases
and were, therefore, excluded from further analyses. Online
Supplementary Figure S4 shows the comparison of the medi-
an expression levels of the remaining 325 miRNA between
ALL subtypes and normal hematopoietic cells. Hierarchical
clustering using these 325 expressed miRNA distinguished
12 clusters of ALL patients and control cases as shown in
Figure 1. Online Supplementary Table S3 shows the genetic
subtype, immunophenotype and karyotype of these
patients. The majority of patients, except for those with
BCR-ABL-positive ALL and ‘B-other’ ALL, clustered per
subtype based on similarities in miRNA expression pat-
tern. For example, all nine E2A-PBX1 patients and nine out
of 11 T-ALL patients clustered into groups based upon sim-
ilarities in their miRNA profiles. Figure 1 also shows that
D. Schotte et al.
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Table 1. Most discriminative miRNA per subtype of pediatric ALL.
Top# miRNA Chromosomal Fold FDR-corrected 
location change P value
MLL-1 let-7b 22q13.31 ↓ 69 <0.001
MLL-2 let-7c 21q21.1 ↓ 16 <0.001
MLL-3 miR-708 11q14.1 ↓ 288 0.002
MLL-4 miR-192 11q13.1 ↓ 3 0.002
MLL-5 miR-196a 17q21.32;12q13.13 ↑ 2283 0.002
MLL-6 miR-194 1q41; 11q13.1 ↓ 3 0.002
MLL-7 miR-497 17p13.1 ↓ 24 0.003
MLL-8 miR-20b Xq26.2 ↓ 6 0.003
MLL-9 miR-133a 18q11.2; 20q13.33 ↑ 47 0.009
MLL-10 miR-372 19q13.41 ↓ 27 0.009
TEL-AML1-1 miR-213 1q31.3 ↓ 5 <0.0001
TEL-AML1-2 miR-99a 21q21.1 ↑ 38 <0.001
TEL-AML1-3 miR-100 11q24.1 ↑ 30 <0.001
TEL-AML1-4 miR-125b 11q24.1; 21q21.1 ↑ 35 <0.001
TEL-AML1-5 miR-126* 9q34.3 ↑ 4 <0.001
TEL-AML1-6 miR-383 8p22 ↑ 1671 <0.001
TEL-AML1-7 miR-221 Xp11.3 ↓ 7 <0.001
TEL-AML1-8 miR-126 9q34.3 ↑ 3 <0.001
TEL-AML1-9 miR-629 15q23 ↑ 4 <0.001
TEL-AML1-10 miR-361-5p Xq21.2 ↓ 2 <0.001
BCR-ABL-1 miR-93 7q22.1 ↓ 2 0.015
BCR-ABL-2 miR-484 16p13.11 ↓ 2 0.015
BCR-ABL-3 miR-331 12q22 ↓ 2 0.023
BCR-ABL-4 miR-103 5q35.1; 20p13 ↓ 2 0.023
BCR-ABL-5 miR-1226 3p21.31 ↓ 2 0.023
BCR-ABL-6 miR-345 14q32.2 ↓ 3 0.024
BCR-ABL-7 miR-210 11p12 ↓ 5 0.024
BCR-ABL-8 miR-301 17q22 ↓ 3 0.024
BCR-ABL-9 miR-324-5p 17p13.1 ↓ 2 0.024
BCR-ABL-10 miR-148b 12q13.13 ↓ 2 0.024
E2A-PBX1-1 miR-126* 9q34.3 ↓ 28 0.001
E2A-PBX1-2 miR-126 9q34.3 ↓ 34 0.001
E2A-PBX1-3 miR-146a 5q33.3 ↓ 14 0.001
E2A-PBX1-4 miR-545 Xq13.2 ↓ 5 0.001
E2A-PBX1-5 miR-24 9q22.32; 19p13.13 ↓ 4 0.001
E2A-PBX1-6 miR-29a 7q32.3 ↓ 3 0.001
E2A-PBX1-7 miR-511 10p12.33 ↓ 706 0.001
E2A-PBX1-8 miR-365 16p13.12; 17q11.2 ↓ 6 0.001
E2A-PBX1-9 miR-30d 8q24.22 ↓ 2 0.001
E2A-PBX1-10 miR-193a 17q11.2 ↓ 8 0.001
hyperdiploid-1 miR-223 Xq11.2 ↑ 4 <0.0001
hyperdiploid-2 miR-222* Xp11.3 ↑ 5 <0.0001
hyperdiploid-3 miR-98 Xp11.22 ↑ 3 <0.0001
hyperdiploid-4 miR-511 10p12.33 ↑ 7 <0.0001
hyperdiploid-5 miR-222 Xp11.3 ↑ 4 <0.001
hyperdiploid-6 miR-660 Xp11.23 ↑ 3 <0.001
hyperdiploid-7 miR-361-3p Xq21.2 ↑ 3 <0.001
hyperdiploid-8 miR-374a Xq13.2 ↑ 3 <0.001
hyperdiploid-9 miR-532-5p Xp11.23 ↑ 3 <0.001
hyperdiploid-10 miR-501-5p Xp11.23 ↑ 3 <0.001
T-ALL-1 miR-191 3p21.31 ↓ 3 <0.0001
T-ALL-2 miR-190 15q22.2 ↑ 6 <0.0001
T-ALL-3 miR-151 8q24.3 ↓ 48 <0.0001
T-ALL-4 miR-425-5p 3p21.31 ↓ 4 <0.0001
T-ALL-5 miR-222* Xp11.3 ↓ 8 <0.0001
T-ALL-6 miR-542-5p Xq26.3 ↑ 234 <0.0001
T-ALL-7 miR-708 11q14.1 ↓ 3884 <0.0001
T-ALL-8 miR-132 17p13.3 ↓ 6 <0.001
T-ALL-9 miR-425-3p 3p21.31 ↓ 3 <0.001
T-ALL-10 miR-342-3p 14q32.2 ↑ 3 <0.001
# The ten most differentially expressed miRNA are listed for each ALL subtype on the
basis of multiple testing (FDR)-corrected P value. The fold-change and P value are
based on the comparison between expression levels of the specified precursor B-ALL
subtype and remaining precursor B-ALL cases (e.g. TEL-AML1 -positive versus non-TEL-
AML1 precursor B-ALL) or between precursor B-ALL and T-lineage ALL cases. miRNA-
targeted genes are listed in Online Supplementary Table S7. * refers to the star strand
of the miRNA duplex that is (partly) complementary to the mature miRNA.continued in the next column
precursor B-ALL patients clustered differently from normal
blood marrow and CD34+ blood cells. For example, the
expression of miR-143 was 70-fold (PFDR=0.0007) lower in
patients with precursor B-ALL than in normal bone mar-
row and the expression of miR-127 was 140-fold
(PFDR=0.001) lower in patients with precursor B-ALL than in
normal CD34+ blood cells. Likewise, the expression pattern
in T-ALL differed from that in normal thymocytes e.g. 28
miRNA were significantly differentially expressed in T-
ALL samples (PFDR ≤0.04; see Online Supplementary Table S2
for relative expression levels).
BCR-ABL-positive and ‘B-other’ precursor B-ALL
patients were spread among other genetic subtypes,
including the hyperdiploid, TEL-AML1 and E2A-PBX1-
positive subtypes, suggesting heterogeneity among BCR-
ABL and ‘B-other’ samples (Figure 1). In line with this, only
16 miRNA with a PFDR less than 0.05 were found for BCR-
ABL-positive patients whereas 50 to 89 miRNA with a PFDR
less than 0.05 were found for other subtypes (Online
Supplementary Table S4). Moreover, these 16 miRNA were
less discriminative for BCR-ABL (fold-change in expression
≤6-fold) than the 50-89 miRNA for the other subtypes
(fold-change in expression ≤3884-fold; Table 1).
The majority of hyperdiploid samples clustered together
and were distinct from other (non-hyperdiploid) ALL sam-
ples based on relatively high expression levels of miR-223,
miR-222/222*, miR-98, and miR-511 (Table 1). Strikingly,
genes encoding these miRNA were all located on chromo-
some 10 or X, two chromosomes of which extra copies can
be found in hyperdiploid cases.27 TEL-AML1–positive ALL
patients were distinguished from those with other (non-
TEL-AML1) genetic subtypes by approximately 5- to 1700-
fold up-regulation of various miRNA including miR-99a,
miR-100, miR-125b, miR-383 and let-7c (PFDR<0.001, Figure
1 and Table 1). In contrast to TEL-AML1 cases, MLL-
rearranged ALL showed a 16-fold down-regulation of let-
7c and a 69-fold lower expression of let-7b compared with
other precursor B-ALL patients negative for MLL-transloca-
tions (PFDR<0.001, Table 1). miRNA profiling revealed two
different subpopulations of TEL-AML1 patients (Figure 1).
Cluster 1 (n=6) displayed similarities in miRNA pattern to
hyperdiploid patients whereas cluster 10 (n=8) did not
share these similarities. At present we do not have an indi-
cation that these two TEL-AML1 sub-clusters differ in clin-
ical outcome. It should, however, be noted that this may be
due to a limited number of relapses in the TEL-AML1 cases
(n=1). Both subtypes were characterized by high expres-
sion of miR-30b miR-151, miR-331 and miR-545 (Figure 1)
microRNA expression profiles in pediatric ALL
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Figure 2. Discriminative expression of miR-125b, miR-99a and miR-
100 between drug-sensitive and -resistant precursor B-ALL patients.
Expression levels relative to snoRNA are shown for miR-125b (A),
miR-99a (B) and miR-100 (C). Dots represent individual samples of
CD34+ selected cells (n=4), normal bone marrow samples ( =7) and
the following precursor B-ALL patients: vincristine-sensitive (n=31;
VCR/sens) and -resistant (n=30; VCR/resist) or daunorubicin-sensi-
tive (n=29; DNR/sens) and -resistant (n=29; DNR/resist). Lines indi-
cate median expression level in each group. The indicated P value
is corrected for multiple-testing (FDR-corrected P value).
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Table 2. miRNA that are differentially expressed between patients with
drug-sensitive and drug-resistant precursor B-ALL.
Top# miRNA Chromosomal Fold FDR corrected 
location change P value
VCR-1 miR-125b 11q24.1; 21q21.1 ↓ 25 0.001
VCR-2 miR-99a 21q21.1 ↑ 21 0.002
VCR-3 miR-100 11q24.1 ↑ 14 0.002
VCR-4 miR-629 15q23 ↑ 3 0.031
VCR-5 miR-126* 9q34.3 ↑ 3 0.032
VCR-6 miR-126 9q34.3 ↑ 3 0.046
VCR-7 miR-9 1q22; 5q14.3; 15q26.1 ↑ 2 0.032
VCR-8 miR-625 14q23.3 ↓ 2 0.006
VCR-9 miR-141 12p13.31 ↓ 2 0.021
VCR-10 miR-200c 12p13.31 ↓ 2 0.001
DNR-1 miR-383 8p22 ↑ 250 0.037
DNR-2 miR-99a 21q21.1 ↑ 21 0.033
DNR-3 miR-125b 11q24.1; 21q21.1 ↑ 20 0.033
DNR-4 miR-100 11q24.1 ↑ 19 0.041
DNR-5 miR-203 14q32.33 ↑ 4 0.041
DNR-6 let-7c 21q21.1 ↑ 4 0.033
DNR-7 miR-126 9q34.3 ↑ 3 0.033
DNR-8 miR-126 9q34.3 ↑ 3 0.033
DNR-9 miR-335 7q32.2 ↑ 3 0.033
DNR-10 miR-199b* 9q34.11 ↑ 2 0.033
ASP-1 miR-454 17q22 ↓ 2 0.017
ASP-2 - - - -
ASP-3 - - - -
ASP-4 - - - -
ASP-5 - - - -
ASP-6 - - - -
ASP-7 - - - -
ASP-8 - - - -
ASP-9 - - - -
ASP-10 - - - -
#miRNA that are differentially expressed between patients sensitive or resistant to vin-
cristine (VCR), daunorubicin (DNR) and L-asparaginase (ASP) are shown and ranked
on the basis of the fold-change in expression level. Fold-change is the ratio in expres-
sion level between resistant and sensitive patients. ↓ represents down-regulation and
↑ refers to up-regulation in resistant cells. * points to the star strand of the miRNA
duplex that is (partly) complementary to the mature miRNA. miRNA-targeted genes are
listed in Online Supplementary Table S9.
and miR-126/126* (Online Supplementary Table S2). This
may indicate a common biological mechanism underlying
the TEL-AML1 and hyperdiploid subtypes. 
MLL-rearranged and E2A-PBX1-positive ALL shared a
high expression level of 15 miRNA including the recently
discovered miR-1979 (Figure 1 and Online Supplementary
Table S5). Forty percent of these 15 miRNA are mapped
within miRNA-clusters e.g. miR-191 and miR-425 on
chromosome 3p21.31 and the cluster of miR-141 and miR-
200c on chromosome 12p13.31. The expression of miR-
191 and miR-425 (Rs=0.8) as well as of miR-141 and miR-
200c (Rs=0.9) correlated well with each other (P<0.001),
which may indicate co-regulation of these miRNA since
they are encoded less than 10 kilobases from each other.
Correlation between expression levels of clustered
miRNA is not restricted to the MLL and E2A-PBX1 sub-
types, since in all ALL cases a strong association was also
observed for miRNA genes within clusters miR-15a-16
(Rs=0.7; P<0.001), miR-17-92 (0.3≤Rs≤0.9; P<0.01), miR-
106b-25 (0.7≤Rs≤0.8; P<0.001), miR-106a-363 (0.3≤
Rs≤0.9; P<0.01), miR-221-222 (Rs=0.8; P<0.001) and miR-
371-373 cluster (0.6≤Rs≤0.8; P<0.001, Online Supplementary
Table S6). 
In Online Supplementary Table S7 we have listed target
genes that were biologically proven (known from litera-
ture) for the miRNA that were found to be differentially
expressed in different subtypes of ALL. Two proven targets
of the let-7 family are RAS and c-MYC. Interestingly,
mRNA levels of RAS and c-MYC were 3- to 5-fold up-reg-
ulated in MLL-rearranged ALL compared to non-MLL pre-
cursor B-ALL (P<0.0001, Online Supplementary Figure S6 and
Figure S7).28 The elevated mRNA expression levels were
associated with a 2-fold up-regulation of c-Myc protein
(P<0.05) in MLL-rearranged patients but not with an up-
regulation of Ras protein as measured by reverse phase
protein detection (M.W.J. Luijendijk, unpublished data,
Online Supplementary Figures S6 and S7). 
Distinct microRNA profiles in drug-sensitive and drug-
resistant patients and their association with clinical out-
come in pediatric acute lymphoblastic leukemia
For 61 out of the 70 patients with precursor B-ALL
included in this study, the in vitro sensitivity to pred-
nisolone, vincristine, L-asparaginase and daunorubicin was
determined. Online Supplementary Table S8 summarizes the
expression levels of 397 miRNA for drug-sensitive and
drug-resistant patients. Sixteen miRNA were discrimina-
tive for resistance to one or more drugs (PFDR <0.05). No
miRNA were associated with prednisolone resistance (PFDR
>0.05), only miR-454 was expressed at a 1.9-fold lower
level in L-asparaginase-resistant cases (PFDR =0.017) whereas
20 miRNA were discriminative for resistance to vincristine
and/or daunorubicin (PFDR <0.05). Table 2 and Online
Supplementary Table S9 show the fold-change for discrimi-
native miRNA and their potential target genes, respective-
ly. The 14- to 25-fold up-regulation of miR-125b, miR-99a
and miR-100 in patients resistant to vincristine (PFDR ≤0.002)
D. Schotte et al.
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Table 3. miRNA associated with clinical outcome in pediatric ALL.
Uncorrected for Corrected for ALL subtype
ALL subtype miRNA hazard confidence P value
N. miRNA P value ratio interval
1 miR-10a 0.018 miR-10a 0.82 0.69 - 0.97 0.020
2 miR-23b 0.019 - - - -
3 miR-27b 0.009 - - - -
4 miR-33 0.025 miR-33 1.32 1.02 - 1.69 0.030
5 miR-99a 0.023 - - - -
6 miR-107 0.028 - - - 
7 miR-125b 0.031 - - - -
8 miR-126* 0.042 - - - -
9 miR-134 0.025 miR-134 0.73 0.56 - 0.96 0.026
10 miR-193a 0.014 - - - 
11 - miR-214 0.73 0.59 - 0.90 0.004
12 - miR-215 1.30 1.01 - 1.67 0.042
13 miR-219 0.033 - - - 
14 miR-223 0.046 - - - 
15 miR-335 0.034 - - - 
16 miR-369-5p 0.049 miR-369-5p 1.30 1.01 - 1.67 0.046
17 miR-371 0.035 - - - 
18 miR-372 0.040 - - - 
19 miR-373 0.044 - - - 
20 miR-449 0.043 - - - 
21 miR-484 0.009 miR-484 0.81 0.69 - 0.94 0.008
22 - miR-496 1.52 1.15 - 2.00 0.003
23 miR-518d 0.047 miR-518d 1.43 1.01 - 2.04 0.046
24 miR-572 0.010 miR-572 0.59 0.41 - 0.85 0.004
25 - miR-580 0.81 0.65 - 0.99 0.045
26 - miR-599 1.39 1.01 - 1.89 0.044
27 - miR-624 0.79 0.67 - 0.93 0.006
28 miR-627 0.028 miR-627 0.68 0.49 - 0.93 0.019
29 let-7c 0.032 - - - -
30 let-7d 0.048 - - - -
31 let-7d* 0.014 - - - -
A Cox proportional hazard model (uncorrected and corrected for ALL subtypes) was
applied to identify which miRNA were related to the clinical outcome of children with
ALL. miRNA expression levels were considered as continuous variables and relapse as
an event. The hazard ratio represents the change in risk of relapse upon each 2-fold
increase in miRNA expression level.
Figure 3. Prognostic value of a miRNA expression profile in newly
diagnosed pediatric ALL. Kaplan-Meier estimates for the probability
of disease-free survival of a miRNA expression profile are shown.
This profile comprises the combined score of 14 miRNA which were,
independently of subtype, predictive for the clinical outcome of newly
diagnosed pediatric ALL cases (see Table 3). See Design and
Methods section for details on how this profile was generated.
Basically, patients were assigned a score of 1 if the expression level
of a given miRNA was associated with a good prognosis and patients
were assigned a score 2 if this expression level was associated with
a poor prognosis. Next, the sum of individual scores of 14 miRNA
was taken which resulted in a minimum score of 14 and a maximum
score of 28. Patients were divided in two groups based on the medi-
an score (of 21) in 78 patients and Kaplan-Meier estimates were cal-
culated. P=0.001, Cox proportional hazard analysis.
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and daunorubicin (PFDR <0.05) is most striking (Figure 2).
Remarkably, 12 out of 31 (39%) and 12 out of 29 (41%)
patients resistant to vincristine and daunorubicin carried
the TEL-AML1 translocation. Cox proportional hazard
analysis revealed that the expression level of 31 miRNA
significantly correlated with the probability of disease-free
survival (P<0.05; Table 3). The prognostic value was inde-
pendent of ALL subtype for 14 miRNA: six miRNA (i.e.
miR-33, -215, -369-5p, -496, -518d, and -599) were associ-
ated with an unfavorable long-term clinical outcome (haz-
ard ratio 1.30–1.52 with 95%CI 1.01–2.04; 0.003≤P≤0.046)
whereas eight miRNA (i.e. miR-10a, -134, -214, -484, -572,
-580, -624 and -627) were linked to a favorable prognosis
(hazard ratio: 0.59–0.82 with 95%CI 0.41–0.99;
0.004≤P≤0.045). Online Supplementary Figure S8 illustrates
the disease-free survival curves associated with each of
these 14 prognostic miRNA in pediatric ALL. Next, ALL
patients were divided into two groups based on the medi-
an cumulative score that combined the expression levels of
these 14 miRNA (Figure 3, see the Design and Methods sec-
tion for details on the cumulative score). Kaplan-Meier
analysis indicated that the profile obtained by combining
information on these 14 miRNA further divided the prog-
nosis; patients with a favorable miRNA expression profile
had a 5-year disease-free survival of 89.4±7% (n=41) com-
pared to 60.8±12% (n=37) for patients with the less favor-
able miRNA profile (P=0.001). 
Discussion
In this study we analyzed the expression levels of 397
miRNA including recently cloned new miRNA in pediatric
ALL by highly specific, stem-looped RT-qPCR miRNA
assays. The results demonstrated that different genetic
subtypes of ALL and drug-resistant cases have unique
miRNA expression profiles and selected miRNA were
associated with the clinical outcome of ALL patients.
Hierarchical clustering of 325 miRNA that are expressed
in ALL cells identified T-ALL, MLL-rearranged ALL, TEL-
AML1, E2A-PBX1 and hyperdiploid ALL-specific miRNA
expression patterns (Figure 1). BCR-ABL and ‘B-other’ ALL
subtypes were not distinguishable as separate groups. This
indicates that BCR-ABL and ‘B-other’ cases are more het-
erogeneous than other subtypes and/or that that miRNA
play a minor role in both subtypes. This is also reflected by
the lower number of miRNA that were significantly differ-
entially expressed as well as the lower fold-change in
expression levels found for miRNA expressed in BCR-ABL
and ‘B-other’ subtypes compared to other (i,e. non-BCR-
ABL and non-‘B-other’) subtypes (Online Supplementary
Table S4 and Table 1). Correspondingly, we and others
found that the BCR-ABL1 and ‘B-other’ subtypes are also
difficult to classify based on mRNA expression levels.20,29,30
Since samples used in both miRNA and mRNA studies
contained more than 90% leukemic cells, the confounding
effect of contaminating normal cells is minimum. This sug-
gests that additional heterogeneity among the BCR-ABL
and ‘B-other’ samples prevents the finding of a characteris-
tic miRNA-profile for each subtype. This explanation is
strengthened by the fact that we recently identified a new
subgroup of pediatric ALL among ‘B-other’ cases which
was characterized by abnormalities in B-cell differentiation
genes.20
MiR-196b, capable of promoting proliferation and sur-
vival of hematopoietic cells,31 was up-regulated in patients
with MLL-rearranged ALL and T-ALL (Online
Supplementary Table S2) which may be driven by activated
HOXA genes in these patients.32 In addition, DNA
hypomethylation of the miR-196b-embedded HOXA area
may contribute to the up-regulation of the miRNA in MLL-
rearranged precursor B-ALL patients.32 As the up-regulation
is specific to the above-mentioned ALL subtypes, these
data imply that the expression and thus biological role of
miRNA depend on the type of cells (cellular context) in
which they are expressed. The issue that we explored here
was to determine which miRNA are discriminative for dif-
ferent genetic subtypes of pediatric ALL. 
We observed two different groups of TEL-AML1 patients
based upon miRNA expression profiles (Figure 1). One
group had a miRNA expression pattern which was most
similar to that of hyperdiploid patients. TEL-AML1 and
hyperdiploid ALL are characterized by high expression of
several miRNA including miR-126/126* (Online
Supplementary Table S2), miR-151 and miR-545 (Figure 1). It
was previously described that miR-126 and miR-126*
inhibit apoptosis, stimulate cell viability in acute myeloid
leukemia cells and enhance proliferation of mouse bone
marrow progenitor cells when up-regulated.33 Also at the
mRNA level, overlapping gene expression profiles can be
detected, supporting the hypothesis that TEL-AML1 and
hyperdiploid ALL have more in common than previously
appreciated.20 Albeit without prognostic difference, the
second group of TEL-AML1-positive patients showed dif-
ferent miRNA expression patterns than the hyperdiploid
patients. The levels of miR-383, miR-125b, miR-100, miR-
99a and let-7c expression were increased by 5- to 1670-fold
in TEL-AML1 patients whereas 3- to 24-fold up-regulation
of miR-222/222*, miR-223, miR-511, and miR-660 was
found in hyperdiploid cases only (Table 1). It should be
noted that the expression level of miR-222/222*, -223, -511
and –660 in hyperdiploid cases cannot simply be explained
by a gene-dosage effect due to an extra copy of chromo-
some 10 and X characteristic of hyperdiploidy. miRNA
specific for either hyperdiploid or TEL-AML1-positive ALL
are of interest because they may point to mechanisms by
which TEL-AML1-positive and hyperdiploid ALL diverge
from the common underlying biology.
We only found a limited number of miRNA associated
with cellular resistance to vincristine, daunorubicin and L-
asparaginase and none with resistance to prednisolone in
pediatric ALL (Table 2). In vitro resistance to these drugs is
associated with an unfavorable outcome in pediatric ALL.11-
14 Remarkably, 39% of the vincristine-resistant patients had
TEL-AML1 subtype ALL, which supports earlier observa-
tions that TEL-AML1-positive patients are resistant to vin-
cristine.34,35 Interestingly, TEL-AML1-positive cases often
show sensitivity to L-asparaginase in combination with
resistance to vincristine.35 We observed here that TEL-
AML1-positive patients and vincristine-resistant cases both
expressed higher levels of miR-125b, which deserves fur-
ther study since this may be linked to the vincristine-resis-
tant/L-asparaginase-sensitive discordant type of TEL-
AML1-positive ALL. Over-expression of miR-125b reduced
the amount of drug-induced apoptosis in pre-B cells36 and
induced proliferation in CD34+ cells.37,38 Interference with
miR-125b function might, therefore, point to a way to sen-
sitize patients to these drugs. 
The expression profile based on 14 miRNA was predic-
tive of the prognosis of ALL (Table 3 and Figure 3). None of
microRNA expression profiles in pediatric ALL
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these miRNA was linked to the occurrence of central nerv-
ous relapses in pediatric ALL as previously reported.39 We
observed that, among others, miR-10a, miR-134 and miR-
214 were linked to a favorable outcome in pediatric ALL,
which may correspond to their described tumor suppressor
activity by driving apoptosis (miR-10a),40 inhibiting cell
proliferation (miR-10a and miR-214),41,42 and down-regulat-
ing oncogene SOX2 (miR-134).43 The expression of all
three miRNA was significantly lower (3- to 600-fold) in
precursor B-ALL than in normal bone marrow or CD34+
cells (Online Supplementary Figure S4). Six miRNA were
associated with an unfavorable prognosis including miR-
33, which was significantly up-regulated in T-ALL com-
pared to in normal thymocytes (Online Supplementary Figure
S4). Besides their prognostic value, these miRNA may also
serve as targets for new therapies. We recently discovered
that down-regulation of miR-10a in MLL-rearranged
patients, due to DNA hypermethylation, could be reversed
and brought back to normal levels by treatment with a
demethylating agent.44 In contrast, antagomirs could be
chosen to down-regulate the expression of aberrantly over-
expressed miRNA with unfavorable prognostic signifi-
cance, such as miR-33. 
In conclusion, we found that different genetic subtypes
of ALL have unique miRNA expression profiles which
point to several miRNA with potential oncogenic and
tumor suppressive activity in ALL. Moreover, our study
indicates that specific miRNA are associated with resist-
ance to vincristine, daunorubicin and L-asparaginase, but
not with resistance to prednisolone. Finally, expression lev-
els of specific miRNA correlate with outcome of pediatric
ALL patients. Collectively, our data form a comprehensive
repository of information on miRNA that are aberrantly
expressed in genetic subtypes of ALL which can be used to
explore the functional role of miRNA in the corresponding
types of pediatric ALL.
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